Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel-Reference-Cited by-同舟云学术

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Published:2024-02-29 Issue:3 Volume:27 Page:566-570
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Lara Primo N.,Mayerson Edward,Gertz Erik,Tangen Catherine,Goldkorn Amir,van Loan Marta,Hussain Maha^ORCID,Gupta Shilpa,Zhang Jingsong^ORCID,Parikh Mamta,Twardowski Przemyslaw,Quinn David I.,LeBlanc Michael,Thompson Ian,Agarwal Neeraj^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Takeda Pharmaceuticals U.S.A.

Jerry and Susan Knapp

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41391-024-00813-3.pdf

Reference9 articles.

1. Whitburn J, Edwards CM. Metabolism in the tumour-bone microenvironment. Curr Osteoporos Rep. 2021;19:494–9. Oct

2. Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.

3. Fortunati N, Gatti F, Felicetti F, Brignardello E. Cancer treatment-induced bone loss in hormone-sensitive cancer: the paradigm of cancer survivor bone health management. Front Horm Res. 2021;54:91–102. PMID: 33946075.

4. Smith MR. Markers of bone metabolism in prostate cancer. Cancer Treat Rev. 2006;32:23–6.

5. Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014;106:dju013.